Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer： findings from the ATHENA study

• Published in: Chinese medical journal Vol. 125; no. 5; pp. 764 - 769
• Main Authors: Xu, Bing-he, Jiang, Ze-fei, Shen, Zhen-zhou, Guan, Zhong-zhen, Chen, Zheng-dong, Cheng, Ying, Zheng, Hong, Jiang, Jun, Wang, Xiao-jia, Tong, Zhong-sheng, Qin, Shu-kui, Luo, Yi, Yao, Min, Wang, Li-wei, He, Jing
• Format: Journal Article
• Language: English
• Published: China Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing 100021, China%Breast Cancer Department, 307 Hospital Cancer Center, Beijing 100071, China%Fudan University Shanghai Cancer Center, Shanghai 200032, China%Cancer Center, SunYat-Sen University, Guangzhou, Guangdong 510060, China%Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China%Jilin Province Cancer Hospital, Changchun, Jilin 130012, China%West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China%Breast Surgery Center, Chongqing Southwest Hospital, Chongqing 400038, China%15th Division of Hematology & Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China%Breast Cancer Department, Tianjin Cancer Hospital, Tianjin 300060, China%Department of Oncology, People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, Jiangsu 210002, China%Hunan Cancer Hospital, Changsha, Hunan 410013, China%Department of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China%Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai 200082, China%Roche Product Development in Asia Pacific, Beiiing 100022 China 01.03.2012
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Bevacizumab; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Bridged-Ring Compounds - adverse effects; Bridged-Ring Compounds - therapeutic use; Female; Humans; Middle Aged; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Taxoids - adverse effects; Taxoids - therapeutic use; Young Adult; 中国人群; 乳腺癌; 单抗; 安全性; 患者; 治疗; 转移性; 阴性; bevacizumab; Chinese; docetaxel; angiogenesis; metastatic breast cancer; first-line
• ISSN: 0366-6999; 2542-5641
• DOI: 10.3760/cma.j.issn.0366-6999.2012.05.008

Background Three randomised trials have demonstrated that combining bevacizumab with first-line chemotherapy significantly improves progression-free survival versus chemotherapy alone in HER2-negative locally recurrent/metastatic breast cancer （LR/mBC）. However, data from Chinese populations are limited and possible differences between ethnic and geographic populations are unknown. This study was conducted to determine whether there are differences in safety and efficacy in patients with HER2-negative LR/mRC between Chinese and Western populations after they receive first-line bevacizumab combined with taxane-based therapy.